In vivo magnetic resonance imaging was used to study the effect of
ancrod (CAS 9046-56-4, Arwin), a plasma
fibrinogen level lowering agent, on brain lesion in two rat models of acute focal cerebral ischaemia. Total lesion volume was determined by multislice T2-weighted magnetic resonance imaging 24 h after permanent
middle cerebral artery occlusion.
Intravenous infusion of
ancrod starting 30 min after
middle cerebral artery occlusion at dosages of 10, 30, 50 or 70 IU/kg (n = 9/group) significantly diminished cerebral lesion volume by 20 to 33% as compared to vehicle-infused controls (n = 12). None of the
ancrod-treated rats showed evidence of intracerebral
bleeding on T2-weighted magnetic resonance images taken after 24 h. In photochemically induced (
rose bengal) unilateral thrombotic cortical
infarction brain damage was displayed by multislice diffusion-weighted magnetic resonance imaging after 24 h. Again, post treatment with
ancrod reduced total volume of cerebral lesion dose-dependently from 142 +/- 28 mm3 in the controls (n = 10) to 121 +/- 28 mm3 (n = 10) and 111 +/- 20 mm3 (n = 11, p < 0.05) in rats treated with 10 and 30 IU/kg
ancrod, respectively (means +/- S.D.). These results suggest cerebroprotection in focal cerebral ischaemia by improvements in the cerebral microcirculation which may offer a potential and safe approach for
therapy of
acute stroke.